This site is intended only for all Healthcare Professionals residing in South Africa
Dosing interruption and/or dose reduction may be required based on individual safety and tolerability. If dose reduction is necessary, then the dose of XALKORI® (crizotinib) should be reduced to 200 mg taken orally twice daily, and if
further dose reduction is necessary, then reduce the dose to 250 mg taken orally once daily. Dose reduction guidelines for haematologic and non-haematologic toxicities are provided in the tables below:
Copyright ©2023 Pfizer South Africa All rights reserved.
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit www.pfizer.co.za.
This website is brought to you by Pfizer South Africa
Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).
Copyright © 2023. Pfizer Laboratories (Pty) Ltd. All rights reserved
These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.
I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to Pfizer.co.za where you will be able to access reference information on Pfizer's prescription medicines.